Does IXEKIZUMAB Cause Tonsillar hypertrophy? 6 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Tonsillar hypertrophy have been filed in association with IXEKIZUMAB (TALTZ). This represents 0.0% of all adverse event reports for IXEKIZUMAB.
6
Reports of Tonsillar hypertrophy with IXEKIZUMAB
0.0%
of all IXEKIZUMAB reports
0
Deaths
2
Hospitalizations
How Dangerous Is Tonsillar hypertrophy From IXEKIZUMAB?
Of the 6 reports, 2 (33.3%) required hospitalization.
Is Tonsillar hypertrophy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for IXEKIZUMAB. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does IXEKIZUMAB Cause?
Injection site pain (3,799)
Psoriasis (2,818)
Drug ineffective (2,759)
Injection site erythema (2,144)
Injection site reaction (1,701)
Injection site swelling (1,615)
Incorrect dose administered (1,032)
Covid-19 (861)
Product dose omission issue (832)
Therapy interrupted (796)
What Other Drugs Cause Tonsillar hypertrophy?
ADALIMUMAB (151)
ONDANSETRON (51)
SOMATROPIN (43)
SECUKINUMAB (42)
DUPILUMAB (39)
METHOTREXATE (39)
INFLIXIMAB (31)
TACROLIMUS (26)
INFLIXIMAB-DYYB (25)
ETANERCEPT (24)
Which IXEKIZUMAB Alternatives Have Lower Tonsillar hypertrophy Risk?
IXEKIZUMAB vs JAKAFI
IXEKIZUMAB vs JANUMET
IXEKIZUMAB vs JANUVIA
IXEKIZUMAB vs JETREA
IXEKIZUMAB vs JUXTAPID